BioSight
Companies
Arcutis Biotherapeutics, Inc. logo

ARQT

NASDAQWESTLAKE VILLAGE, CA
Arcutis Biotherapeutics, Inc.

Arcutis develops topical and systemic drugs for immune-related skin diseases. The pipeline includes ZORYVE (roflumilast), a cream and foam formulation already approved at multiple strengths, along with earlier-stage candidate ARQ-234, with potential label expansions planned for existing products. Arcutis is in commercial and clinical development stages, having brought at least one product to market while continuing to advance other candidates through development.

Price history not yet available for ARQT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar